Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.58 |
| ▸ | CA12 | O43570 | 1/20 | 0.56 |
| ▸ | CA7 | P43166 | 1/20 | 0.56 |
| ▸ | CA9 | Q16790 | 1/20 | 0.56 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | ATM | Q13315 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.53 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.53 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.53 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.53 |
| ▸ | NCOR2 | Q9Y618 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | MAOA | P21397 | 1/20 | 0.50 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL28846002 | 0.98 | LTA4H (0.57) | LTA4HCA12CA7CA9CA14 | |
| SCHEMBL8850869 | 0.90 | HDAC3 (0.58) | CA12CA7CA9CA14MEN1 | |
| Hydrochloric Acid SCHEMBL28493003 | 0.88 | HDAC3 (0.56) | CA12CA7CA9CA14MEN1 | |
| SCHEMBL19438874 | 0.88 | HDAC3 (0.65) | CA12CA7CA9CA14MEN1 | |
| SCHEMBL3143537 | 0.87 | LTA4H (0.64) | LTA4HMEN1KMT2AATM | |
| SCHEMBL16730575 | 0.87 | HDAC3 (0.66) | MEN1KMT2AATMALDH1A1HDAC3 | |
| SCHEMBL13903744 | 0.87 | HDAC3 (0.66) | MEN1KMT2AATMALDH1A1HDAC3 | |
| SCHEMBL16503433 | 0.85 | LTA4H (0.48) | LTA4HCA12CA7CA9CA14 | |
| SCHEMBL549268 | 0.85 | LTA4H (0.60) | LTA4HMEN1KMT2ATDP1ATM | |
| SCHEMBL13870210 | 0.84 | CHRM2 (0.53) | LTA4HCA12CA7CA9CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117447334-A | Method for efficiently synthesizing alpha-amino acetal | 南京工业大学 | 2024-01-26 | — | — | CN | claimed |
| US-20260108618-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | CIDARA THERAPEUTICS, INC. | 2026-04-23 | — | — | US | disclosed |
| EP-4719602-A1 | ANTI-HIV COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2026-04-08 | — | — | EP | disclosed |
| US-12569565-B2 | Compositions and methods for the treatment of viral infections | CIDARA THERAPEUTICS, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| US-12427200-B2 | Compositions and methods for the treatment of viral infections | CIDARA THERAPEUTICS, INC. (US) | 2025-09-30 | — | — | US | disclosed |
| US-20250051375-A1 | ANTI-HIV COMPOUNDS | GILEAD SCIENCES, INC. | 2025-02-13 | — | — | US | disclosed |
| WO-2024249517-A1 | ANTI-HIV COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2024-12-05 | — | — | WO | disclosed |
| WO-2024232599-A1 | NOVEL BENZOTHIOPHENE DERIVATIVE INHIBITING BET PROTEIN AND COMPOSITION FOR TREATMENT OF CANCER, USING SAME | 주식회사 베노바이오 | 2024-11-14 | — | — | WO | disclosed |
| US-20240156975-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | CIDARA THERAPEUTICS, INC. | 2024-05-16 | — | — | US | disclosed |
| EP-4328230-A2 | AMINO ACID COMPOUNDS AND METHODS OF USE | Pliant Therapeutics, Inc. (US) | 2024-02-28 | — | — | EP | disclosed |
| WO-2001009126-A1 | SEROTONERGIC BENZOTHIOPHENES | ELI LILLY AND COMPANY (US) | 2001-02-08 | — | — | WO | disclosed |
| CN-1053472-C | Oligonucleotides derived from the SOD family | HOFFMANN LA ROCHE (CH) | 2000-06-14 | — | — | CN | disclosed |
| CN-1041091-C | Trisubstituted pyrimido [5,4-d] pyrimidines for modulating | THOMAE GMBH DR K (DE) | 1998-12-09 | — | — | CN | disclosed |
| US-5618814-A | Trisubstituted pyrimido [5,4-d] pyrimidines for modulating multi-drug resistance and pharmaceutical compositions containing these compounds | DR. KARL THOMAE GMBH (DE) | 1997-04-08 | — | — | US | disclosed |
| CN-1106405-A | Trisubstituted pyrimido [5,4-d] pyrimidines for modulating | THOMAE GMBH DR K (DE) | 1995-08-09 | — | — | CN | disclosed |
| US-4652560-A | ANTIBIOTICS, BACTERICIDES | BEECHAM GROUP P.L.C. (GB) | 1987-03-24 | — | — | US | disclosed |
| US-4539202-A | SYNERGISTIC MIXTURE WITH PENICILLINS | BEECHAM GROUP P.L.C. (GB) | 1985-09-03 | — | — | US | disclosed |
| EP-0025271-B1 | DERIVATIVES OF CLAVULANIC ACID, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | BEECHAM GROUP PLC (GB) | 1984-03-14 | — | — | EP | disclosed |
| EP-0025271-A1 | Derivatives of clavulanic acid, their preparation and pharmaceutical compositions containing them | BEECHAM GROUP PLC (GB) | 1981-03-18 | — | — | EP | disclosed |
| US-4231933-A | Novel 3-hydroxy-pyrrolin-2-one derivatives | WARNER-LAMBERT COMPANY (US) | 1980-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12427200-B2 | Compositions and methods for the treatment of viral infections | FCGR3B, ALB, FCGR1A | LTA4H 1204/4885CA12 399/4885CA7 805/4885 |
| US-20250051375-A1 | ANTI-HIV COMPOUNDS | CCR5, CD4, NFATC1 | LTA4H 2455/4885CA12 4488/4885CA7 3634/4885 |
| US-20260108618-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | FCGR3B, FCGR1A, FCGR2A | LTA4H 1939/4885CA12 1209/4885CA7 1239/4885 |
| US-12569565-B2 | Compositions and methods for the treatment of viral infections | ALB, FCGR3B, FCGR1A | LTA4H 1363/4885CA12 1326/4885CA7 1036/4885 |
| US-20240156975-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | FCGR3B, ALB, FCGR1A | LTA4H 1204/4885CA12 399/4885CA7 805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.